Elevation Oncology, Inc. Logo

Elevation Oncology, Inc.

ELEV

(1.2)
Stock Price

0,53 USD

-34.65% ROA

-57.97% ROE

-0.78x PER

Market Cap.

30.877.392,00 USD

38.21% DER

0% Yield

-68453.45% NPM

Elevation Oncology, Inc. Stock Analysis

Elevation Oncology, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Elevation Oncology, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.34x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (48%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-104.6%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-56.86%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Elevation Oncology, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Elevation Oncology, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Elevation Oncology, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Elevation Oncology, Inc. Revenue
Year Revenue Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Elevation Oncology, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 5.338.000
2020 15.476.000 65.51%
2021 23.595.000 34.41%
2022 78.717.000 70.03%
2023 29.688.000 -165.15%
2023 25.434.000 -16.73%
2024 26.204.000 2.94%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Elevation Oncology, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 816.000
2020 1.800.000 54.67%
2021 8.451.000 78.7%
2022 15.832.000 46.62%
2023 13.992.000 -13.15%
2023 14.904.000 6.12%
2024 17.648.000 15.55%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Elevation Oncology, Inc. EBITDA
Year EBITDA Growth
2019 -5.882.000
2020 -17.261.000 65.92%
2021 -32.028.000 46.11%
2022 -94.549.000 66.13%
2023 -43.680.000 -116.46%
2023 -40.299.000 -8.39%
2024 -43.836.000 8.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Elevation Oncology, Inc. Gross Profit
Year Gross Profit Growth
2019 0
2020 -15.000 100%
2021 -18.000 16.67%
2022 -27.000 33.33%
2023 0 0%
2023 -39.000 100%
2024 -16.000 -143.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Elevation Oncology, Inc. Net Profit
Year Net Profit Growth
2019 -5.882.000
2020 -17.265.000 65.93%
2021 -32.039.000 46.11%
2022 -95.080.000 66.3%
2023 -42.544.000 -123.49%
2023 -45.704.000 6.91%
2024 -41.844.000 -9.22%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Elevation Oncology, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 -1 0%
2021 -1 100%
2022 -4 75%
2023 -1 -300%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Elevation Oncology, Inc. Free Cashflow
Year Free Cashflow Growth
2019 -5.450.000
2020 -12.369.000 55.94%
2021 -30.167.000 59%
2022 -85.569.000 64.75%
2023 -56.180.000 -52.31%
2023 -13.357.000 -320.6%
2024 -8.205.000 -62.79%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Elevation Oncology, Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 -5.450.000
2020 -12.298.000 55.68%
2021 -30.167.000 59.23%
2022 -85.483.000 64.71%
2023 -56.180.000 -52.16%
2023 -13.357.000 -320.6%
2024 -8.205.000 -62.79%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Elevation Oncology, Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 0
2020 71.000 100%
2021 0 0%
2022 86.000 100%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Elevation Oncology, Inc. Equity
Year Equity Growth
2019 -5.873.000
2020 -23.081.000 74.55%
2021 140.697.000 116.4%
2022 49.032.000 -186.95%
2023 54.809.000 10.54%
2023 62.416.000 12.19%
2024 80.918.000 22.87%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Elevation Oncology, Inc. Assets
Year Assets Growth
2019 1.914.000
2020 80.907.000 97.63%
2021 149.494.000 45.88%
2022 94.161.000 -58.76%
2023 89.091.000 -5.69%
2023 99.975.000 10.89%
2024 114.597.000 12.76%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Elevation Oncology, Inc. Liabilities
Year Liabilities Growth
2019 7.787.000
2020 103.988.000 92.51%
2021 8.797.000 -1082.08%
2022 45.129.000 80.51%
2023 34.282.000 -31.64%
2023 37.559.000 8.72%
2024 33.679.000 -11.52%

Elevation Oncology, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.67
Price to Earning Ratio
-0.78x
Price To Sales Ratio
532.37x
POCF Ratio
-0.71
PFCF Ratio
-0.71
Price to Book Ratio
0.38
EV to Sales
40.46
EV Over EBITDA
-0.06
EV to Operating CashFlow
-0.05
EV to FreeCashFlow
-0.05
Earnings Yield
-1.29
FreeCashFlow Yield
-1.4
Market Cap
0,03 Bil.
Enterprise Value
0,00 Bil.
Graham Number
4.56
Graham NetNet
1.31

Income Statement Metrics

Net Income per Share
-0.67
Income Quality
1.09
ROE
-0.58
Return On Assets
-0.35
Return On Capital Employed
-0.35
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-684.45
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
259.02
Research & Developement to Revenue
425.43
Stock Based Compensation to Revenue
53.03
Gross Profit Margin
0.43
Operating Profit Margin
-684.45
Pretax Profit Margin
-683.81
Net Profit Margin
-684.53

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.73
Free CashFlow per Share
-0.73
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.36
Return on Tangible Assets
-0.35
Days Sales Outstanding
0
Days Payables Outstanding
3804.85
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.1
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,88
Book Value per Share
1,37
Tangible Book Value per Share
1.37
Shareholders Equity per Share
1.37
Interest Debt per Share
0.61
Debt to Equity
0.38
Debt to Assets
0.27
Net Debt to EBITDA
0.72
Current Ratio
41.1
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
0,08 Bil.
Invested Capital
110851000
Working Capital
0,11 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Elevation Oncology, Inc. Dividends
Year Dividends Growth

Elevation Oncology, Inc. Profile

About Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

CEO
Mr. Joseph J. Ferra Jr.
Employee
29
Address
888 Seventh Avenue
New York, 10106

Elevation Oncology, Inc. Executives & BODs

Elevation Oncology, Inc. Executives & BODs
# Name Age
1 Dr. David Dornan Ph.D.
Chief Scientific Officer
70
2 Mr. Robert C. Yang
Vice President of Legal Affairs
70
3 Ms. Valerie Malyvanh Jansen M.D., Ph.D.
Chief Medical Officer
70
4 Ms. Tammy Furlong CPA, P.M.P.
Chief Financial Officer & Secretary
70
5 Candice Masse
Senior Director of Corporate Communications & Investor Relations
70
6 Mr. Joseph J. Ferra Jr.
Chief Executive Officer, President & Director
70
7 Mr. Biren Shah
Senior Vice President of Business & Corporate Development
70
8 Mr. Ryan Bloomer
Head of Tech Ops
70

Elevation Oncology, Inc. Competitors